Tugba Bagci Onder

DDRKOL identifies essential DDR genes in glioblastoma using CRISPR screens, revealing four high-confidence candidates validated across multiple assays and models.

This study identifies BRD9 inhibition as a strategy to enhance radiosensitivity in glioblastoma by modulating the MYC pathway, without significant cytotoxicity under normal conditions.

This study identifies CBP/p300 inhibition as a strategy to overcome vincristine resistance in medulloblastoma by targeting genes involved in drug resistance.

The paper identifies HDAC6 as an epigenetic vulnerability in TMZ-resistant glioblastoma models and shows HDAC6 inhibitors can restore TMZ sensitivity.

This paper develops EGFRvIII-targeted virus-like particles (VLPs) that enable selective genome editing and elimination of glioblastoma cells while sparing non-target cells.

The paper identifies BRPF1 as a key regulator of Taxol resistance in TNBC through genetic and chemical screens, showing its inhibition sensitizes resistant cells to chemotherapy.

This study identifies RBBP4 as a critical regulator of cell cycle progression in TMZ-resistant glioblastoma through CRISPR screens and functional analyses.

This paper develops ACE2-coated virus-like particles (ACE2-VLPs) that effectively neutralize SARS-CoV-2, including variants, and show superior efficacy compared to ACE2-expressing extracellular vesicles.

This study identifies BRPF reader proteins and epigenetic regulators as targets to overcome taxane resistance in prostate cancer by reversing ABCB1-mediated efflux and restoring taxane susceptibility.

This study shows HOXB13 promotes prostate cancer proliferation by altering chromatin accessibility through interactions with the SWI/SNF complex, particularly in AR-negative castration-resistant prostate cancer.

The paper develops multimeric sACE2 decoys using SunTag or MoonTag systems, showing >100-fold increased SARS-CoV-2 neutralization compared to monomeric sACE2.